Clinical Trials Browser

Phase 1/2 × Active not recruiting × Carcinoma, Transitional Cell × Clear all

NCT03854474 2026-03-18

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05562830 2026-03-16

MK-3475-04A

Phase 1/2 Active not recruiting

Carcinoma, Transitional Cell

NCT06483334 2026-02-18

MK-3475-04C

Phase 1/2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT05544552 2026-01-12

SURF301

Phase 1/2 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis, Urologic Neoplasms

NCT02989584 2026-01-07

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04863885 2025-12-17

Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05661955 2025-11-21

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

Phase 1/2 Active not recruiting

DermatologicGenitourinary

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma

NCT02420847 2025-11-10

Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

Phase 1/2 Active not recruiting

Carcinoma, Transitional Cell

NCT03288545 2025-11-10

EV-103

Phase 1/2 Active not recruiting

348 enrolled 1 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT05845814 2025-09-10

MK-3475-04B

Phase 1/2 Active not recruiting

Carcinoma, Transitional Cell

NCT00365157 2025-07-11

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

Phase 1/2 Active not recruiting

Carcinoma, Transitional Cell

NCT04152499 2025-05-20

MK-2870-001

Phase 1/2 Active not recruiting

BreastGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma

NCT04902872 2025-01-23

Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Phase 1/2 Active not recruiting

BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Ovarian Epithelial, Appendiceal Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT05620134 2024-10-15

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Phase 1/2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms